Project Grant HT94252510604
Award Date
9/30/25
Completion Date
9/29/27
Dollars Obligated
$481K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Davis, CA, USA
Similar Awards
This Project Grant award of $636,285 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of California, Davis (UC Davis) on "TRIPLE AKR1C3/COX2/SEH INHIBITION FOR THE TREATMENT OF LETHAL PROSTATE CANCER." The funding will be used over a 3-year period from September 2023 to August 2026 to conduct basic, translational, and clinical research aimed at developing new treatments for prostate cancer, a key health...
This federal Project Grant award of $1,801,179.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research at the University of California, Davis aimed at transforming healthcare for military service members, veterans, and the broader public. The research project, titled "CONTRIBUTION OF BONE MASS AND FRACTURE TO BONE METASTASIS IN PROSTATE CANCER," will investigate innovative approaches to...
This Project Grant award for $810,472, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at the University of California, Davis aimed at the development of a triple inhibitor treatment for lethal prostate cancer. The research is focused on simultaneously inhibiting the AKR1C3, COX2, and SEH enzymes, which play key roles in the progression of aggressive forms of prostate cancer. The award has a performance period...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public...
The University of California, Davis was awarded a $1,446,250 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to conduct research on "THERAPEUTIC TARGETING OF A NOVEL TUMOR-INTRINSIC SIGNALING PATHWAY FOR LETHAL PROSTATE CANCER." The award period is from August 1, 2023 to July 31, 2026. UC Davis will leverage its expertise in medical research to investigate potential medical solutions relevant to the...
The University of California, Davis was awarded a $1,177,500 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will fund research to target a key tumor plasticity driver in lethal prostate cancer. Through August 2021 to July 2024, UC Davis researchers will investigate medical solutions for prostate cancer on the cellular level with the aim of transforming patient care and outcomes. The...
The University of California, Davis was awarded a $1,446,009 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to target CD200/CD200R signaling as a novel strategy for treating therapy-resistant prostate cancer. The grant, awarded July 1, 2023 and set to be completed by June 30, 2026, will support research into medical solutions for prostate cancer that remains unresponsive to standard treatments by...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,615,000.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at "DISCOVERING TRANSCRIPTIONAL DRIVERS OF THERAPY-RESISTANT METASTATIC PROSTATE CANCER". The award period runs from May 1, 2024 to April 30, 2027. As a leading academic medical center, UCSF has a strong track record of...
The Regents of the University of California, San Francisco was awarded a $1,202,954 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from April 1, 2022 to March 31, 2026 to improve informed decision-making for precision oncology in Veterans with advanced prostate cancer. Through basic, applied, and advanced biomedical research supported by this program, the...
The University of California, San Diego (UCSD) was awarded a $1,218,012 Project Grant from the Defense Health Agency on September 30, 2023 under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "GERMLINE INFLUENCE ON PROSTATE CANCER METASTASIS AND TREATMENT RESPONSE." The research aims to transform health care for Service Members and the American public by investigating medical solutions for the battlefield through innovative and impactful...